iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
152 hedge funds and large institutions have $768M invested in iTeos Therapeutics in 2022 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 72 increasing their positions, 32 reducing their positions, and 31 closing their positions.
282% more call options, than puts
Call options by funds: $5.65M | Put options by funds: $1.48M
125% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 32
2.92% more ownership
Funds ownership: 101.59% → 104.5% (+2.9%)
10% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 31
4% less funds holding
Funds holding: 159 → 152 (-7)
34% less capital invested
Capital invested by funds: $1.17B → $768M (-$398M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$18.2M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$12.8M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$12.6M |
| 4 |
BlackRock
New York
|
+$9.25M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$9.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$24.6M |
| 2 |
RI
RTW Investments
New York
|
-$15.7M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$14.5M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$14.3M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$11.5M |
ITOS Hedge Fund Activity: Q2 2022 in Review
152 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q2 2022, worth a combined $768M — down 34% from $1.17B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of ITOS and 28 opened new positions — a net loss of 3 holders — while 32 trimmed existing stakes and 72 added.
The largest buyer was State Street, adding an estimated $18.2M. The largest seller was Boxer Capital, cutting an estimated $24.6M.
- 152 institutional investors held iTeos Therapeutics (ITOS) as of Q2 2022, down from 159 in Q1 2022.
- Funds reported $768M of iTeos Therapeutics stock for Q2 2022, down 34% quarter-over-quarter.
- 28 funds opened new iTeos Therapeutics positions in Q2 2022 and 31 closed out, a net change of -3 holders.
- The largest iTeos Therapeutics buyer in Q2 2022 was State Street, an estimated $18.2M added.
- The largest iTeos Therapeutics seller in Q2 2022 was Boxer Capital, an estimated $24.6M sold.
Based on aggregated 13F filings for Q2 2022.